204 related articles for article (PubMed ID: 11923801)
1. Antiarrhythmic effects of azimilide in paroxysmal supraventricular tachycardia: efficacy and dose-response.
Page RL; Connolly SJ; Wilkinson WE; Marcello SR; Schnell DJ; Pritchett EL;
Am Heart J; 2002 Apr; 143(4):643-9. PubMed ID: 11923801
[TBL] [Abstract][Full Text] [Related]
2. Azimilide for the treatment of atrial fibrillation, atrial flutter, and paroxysmal supraventricular tachycardia: results of a randomized trial and insights on the concordance of symptoms and recurrent arrhythmias.
Page RL; Pritchett EL; Connolly S; Wilkinson WE;
J Cardiovasc Electrophysiol; 2008 Feb; 19(2):172-7. PubMed ID: 17916138
[TBL] [Abstract][Full Text] [Related]
3. Antiarrhythmic effects of azimilide in atrial fibrillation: efficacy and dose-response. Azimilide Supraventricular Arrhythmia Program 3 (SVA-3) Investigators.
Pritchett EL; Page RL; Connolly SJ; Marcello SR; Schnell DJ; Wilkinson WE
J Am Coll Cardiol; 2000 Sep; 36(3):794-802. PubMed ID: 10987602
[TBL] [Abstract][Full Text] [Related]
4. Dose-response relations of azimilide in the management of symptomatic, recurrent, atrial fibrillation.
Connolly SJ; Schnell DJ; Page RL; Wilkinson WE; Marcello SR; Pritchett EL
Am J Cardiol; 2001 Nov; 88(9):974-9. PubMed ID: 11703992
[TBL] [Abstract][Full Text] [Related]
5. Azimilide.
Clemett D; Markham A
Drugs; 2000 Feb; 59(2):271-7; discussion 278-9. PubMed ID: 10730550
[TBL] [Abstract][Full Text] [Related]
6. Azimilide for atrial fibrillation: clinical trial results and implications.
Pritchett EL; Marcello SR
Card Electrophysiol Rev; 2003 Sep; 7(3):215-9. PubMed ID: 14739716
[TBL] [Abstract][Full Text] [Related]
7. Asymptomatic or "silent" atrial fibrillation: frequency in untreated patients and patients receiving azimilide.
Page RL; Tilsch TW; Connolly SJ; Schnell DJ; Marcello SR; Wilkinson WE; Pritchett EL;
Circulation; 2003 Mar; 107(8):1141-5. PubMed ID: 12615792
[TBL] [Abstract][Full Text] [Related]
8. Mortality in patients after a recent myocardial infarction: a randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification.
Camm AJ; Pratt CM; Schwartz PJ; Al-Khalidi HR; Spyt MJ; Holroyde MJ; Karam R; Sonnenblick EH; Brum JM;
Circulation; 2004 Mar; 109(8):990-6. PubMed ID: 14967728
[TBL] [Abstract][Full Text] [Related]
9. A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. UK Propafenone PSVT Study Group.
Circulation; 1995 Nov; 92(9):2550-7. PubMed ID: 7586356
[TBL] [Abstract][Full Text] [Related]
10. Antiarrhythmic efficacy of azimilide in patients with atrial fibrillation. Maintenance of sinus rhythm after conversion to sinus rhythm.
Pritchett EL; Kowey P; Connolly S; Page RL; Kerr C; Wilkinson WE;
Am Heart J; 2006 May; 151(5):1043-9. PubMed ID: 16644334
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of azimilide for the maintenance of sinus rhythm in patients with paroxysmal atrial fibrillation in the presence and absence of structural heart disease.
Kerr CR; Connolly SJ; Kowey P; Page RL; Pritchett EL; Ruda MY; Ruzyllo W; Wilkinson WE;
Am J Cardiol; 2006 Jul; 98(2):215-8. PubMed ID: 16828595
[TBL] [Abstract][Full Text] [Related]
12. Effects of azimilide on heart rate and ECG conduction intervals during sinus rhythm in patients with a history of atrial fibrillation.
Pritchett EL; Schulte MC; Schnell D; Marcello SR; Wilkinson WE; Page RL; Connolly SJ;
J Clin Pharmacol; 2002 Apr; 42(4):388-94. PubMed ID: 11936563
[TBL] [Abstract][Full Text] [Related]
13. Cumulative experience of azimilide-associated torsades de pointes ventricular tachycardia in the 19 clinical studies comprising the azimilide database.
Pratt CM; Al-Khalidi HR; Brum JM; Holroyde MJ; Schwartz PJ; Marcello SR; Borggrefe M; Dorian P; Camm AJ;
J Am Coll Cardiol; 2006 Aug; 48(3):471-7. PubMed ID: 16875971
[TBL] [Abstract][Full Text] [Related]
14. Azimilide dihydrochloride, a novel antiarrhythmic agent.
Karam R; Marcello S; Brooks RR; Corey AE; Moore A
Am J Cardiol; 1998 Mar; 81(6A):40D-46D. PubMed ID: 9537222
[TBL] [Abstract][Full Text] [Related]
15. Azimilide vs. placebo and sotalol for persistent atrial fibrillation: the A-COMET-II (Azimilide-CardiOversion MaintEnance Trial-II) trial.
Lombardi F; Borggrefe M; Ruzyllo W; Lüderitz B;
Eur Heart J; 2006 Sep; 27(18):2224-31. PubMed ID: 16935870
[TBL] [Abstract][Full Text] [Related]
16. Azimilide dihydrochloride: a unique class III antiarrhythmic agent.
Tran HT
Heart Dis; 1999; 1(2):114-6. PubMed ID: 11720612
[TBL] [Abstract][Full Text] [Related]
17. Safety and utility of flecainide acetate in the routine care of patients with supraventricular tachyarrhythmias: results of a multicenter trial. The Flecainide Supraventricular Tachycardia Study Group.
Hopson JR; Buxton AE; Rinkenberger RL; Nademanee K; Heilman JM; Kienzle MG
Am J Cardiol; 1996 Jan; 77(3):72A-82A. PubMed ID: 8607395
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular systolic dysfunction: results from the Azimilide Postinfarct Survival Evaluation (ALIVE) trial.
Pratt CM; Singh SN; Al-Khalidi HR; Brum JM; Holroyde MJ; Marcello SR; Schwartz PJ; Camm AJ;
J Am Coll Cardiol; 2004 Apr; 43(7):1211-6. PubMed ID: 15063432
[TBL] [Abstract][Full Text] [Related]
19. The azimilide post-infarct survival evaluation (ALIVE) trial.
Camm AJ; Karam R; Pratt CM
Am J Cardiol; 1998 Mar; 81(6A):35D-39D. PubMed ID: 9537221
[TBL] [Abstract][Full Text] [Related]
20. Azimilide dihydrochloride: a new class III anti-arrhythmic agent.
Abrol R; Page RL
Expert Opin Investig Drugs; 2000 Nov; 9(11):2705-15. PubMed ID: 11060832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
